bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: D N O S A J J M A M F J
2016: D

 
  Other news for:
Hematologic Diseases
 Resources from HONselect
It's Snakes to the Rescue for Heart Patients
Venom from one slithery serpent might be source of a better blood thinner, early research suggests

By Robert Preidt

THURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.

Taiwanese scientists say a blood thinner drug based on venom from the Wagler's pit viper was effective in mice, and might prove safer than current anti-clotting meds for humans one day.

The serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.

"Blood thinner medications have a long and storied history with snake venom," said Dr Satjit Bhysri, a heart specialist at Lenox Hill Hospital in New York City. In fact, "many current blood thinners are based on initial experiments from proteins found in snake venom," he added.

In the new study, a team led by Tur-Fu Huang, a pharmacology researcher at National Taiwan University, focused on the venom of the Tropidolaemuswaglerix snake -- a Southeast Asian species known as Wagler's pit viper or the Temple viper.

The snake's venom contains a protein called trowaglerix, the researchers explained. Designing a molecule based on trowaglerix, Huang's group was able to block GPVI -- a protein that sits on the surface of blood platelet cells and is crucial to allowing these cells to clump together and form clots.

When mixed with blood, the new compound prevented blood cells called platelets from clotting. Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice. Still, experiments in animals often don't translate to success in humans, so further research is needed.

Dr. Kevin Marzo is head of cardiology at NYU Winthrop Hospital in Mineola, N.Y. Reviewing the findings, he agreed that the drug under development may have merit.

"Many of the lifesaving drugs used in the treatment of heart attack patients work by inhibiting platelets and preventing blood clotting. However, it is often at the cost of serious bleeding complications," he said.

"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation," Marzo added.

The study was published June 8 in the journal Arteriosclerosis, Thrombosis and Vascular Biology.

More information

The American Heart Association has more on anti-clotting drugs.

SOURCES: Satjit Bhusri, M..D, cardiologist, Lenox Hill Hospital, New York City; Kevin Marzo, M.D., chief, division of cardiology, NYU Winthrop Hospital in Mineola, N.Y.; Arteriosclerosis, Thrombosis and Vascular Biology, news release, June 8, 2016

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=723397

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Blood
Heart
Venoms
Blood Platelets
Cells
Arteriosclerosis
Research Personnel
Specialty Chemicals and Products
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Inicio img Sobre nosotros img Rincón de la prensa img Boletín HON img Mapa del sitio img Política ética img Contactos